• The Call That No Parent Wants to Receive
  • Epidiolex May Interact With Diacomit But With Depacon Seems OK, Small Trial Finds
  • Fintepla Approval ‘Fills Us With a Lot of Pride,’ Zogenix CEO Says in Interview
  • National Survey Seeks to Assess Full Social, Economic Burdens of Rare Diseases in US
  • UK Eases Restrictions on Epidyolex for Treating Epileptic Disorders
  • Enrollment Opens in MONARCH Trial Testing STK-001 in Young Patients
  • Fintepla Earns FDA Approval for Treatment of Seizures in Dravet Syndrome
  • Alexion Charitable Foundation Giving $1.1M to Assist Rare Disease Community During Pandemic
  • Epilepsy Surgery May Not Be Advised in Dravet With SCN1A Mutations, Study Finds
  • CBD May Have Its Own Anti-epileptic Properties, Regardless of Clobazam Use
  • Coalition Will Address Racial Disparities in Rare Disease Communities
  • ‘Shine Forward with Dravet’ Is Online Support for Families of Patients